Candriam S.C.A. Halozyme Therapeutics, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 174,578 shares of HALO stock, worth $9.42 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

174,578

Previous 100,813 73.17%

Holding current value

$9.42 Million

Previous $5.28 Million 89.22%

% of portfolio

0.06%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$51.3 - $64.42 $3.78 Million - $4.75 Million	73,765 Added 73.17%	174,578 $9.99 Million
Q2 2024 Aug 05, 2024	SELL	$37.81 - $52.4 $3.03 Million - $4.2 Million	-80,184 Reduced 44.3%	100,813 $5.28 Million
Q1 2024 May 03, 2024	SELL	$33.68 - $41.95 $3.04 Million - $3.78 Million	-90,143 Reduced 33.25%	180,997 $7.36 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $2 Million - $2.53 Million	-60,001 Reduced 18.12%	271,140 $10 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $1.13 Million - $1.37 Million	-31,002 Reduced 8.56%	331,141 $12.6 Million
Q2 2023 Aug 08, 2023	SELL	$30.28 - $38.74 $1.08 Million - $1.39 Million	-35,807 Reduced 9.0%	362,143 $13.1 Million
Q1 2023 May 12, 2023	SELL	$32.86 - $55.7 $8.36 Million - $14.2 Million	-254,352 Reduced 38.99%	397,950 $15.2 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $55,002 - $81,611	-1,373 Reduced 0.21%	652,302 $37.1 Million
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $2.74 Million - $3.69 Million	71,178 Added 12.22%	653,675 $25.8 Million
Q2 2022 Aug 03, 2022	SELL	$37.35 - $48.3 $4.58 Million - $5.92 Million	-122,509 Reduced 17.38%	582,497 $25.6 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $2,333 - $2,997	-73 Reduced 0.01%	705,006 $28.1 Million
Q4 2021 Feb 10, 2022	BUY	$31.82 - $40.75 $225,922 - $289,325	7,100 Added 1.02%	705,079 $28.4 Million
Q3 2021 Nov 09, 2021	BUY	$38.47 - $46.42 $5.73 Million - $6.92 Million	149,049 Added 27.15%	697,979 $28.4 Million
Q2 2021 Jul 20, 2021	SELL	$38.84 - $51.31 $7.18 Million - $9.48 Million	-184,812 Reduced 25.19%	548,930 $24.9 Million
Q1 2021 Apr 29, 2021	SELL	$39.51 - $51.45 $474 - $617	-12 Reduced -0.0%	733,742 $30.1 Million
Q4 2020 Jan 22, 2021	SELL	$25.81 - $43.62 $8.07 Million - $13.6 Million	-312,718 Reduced 29.88%	733,754 $31.3 Million
Q3 2020 Oct 19, 2020	BUY	$25.74 - $29.63 $1.28 Million - $1.47 Million	49,594 Added 4.97%	1,046,472 $27.5 Million
Q2 2020 Jul 23, 2020	BUY	$16.25 - $26.81 $2.95 Million - $4.87 Million	181,559 Added 22.27%	996,878 $26.7 Million
Q1 2020 May 26, 2020	BUY	$13.9 - $21.83 $653 - $1,026	47 Added 0.01%	815,319 $14.1 Million
Q4 2019 Jan 21, 2020	BUY	$14.93 - $19.53 $2.51 Million - $3.28 Million	168,193 Added 25.99%	815,272 $14,000
Q3 2019 Oct 21, 2019	BUY	$15.2 - $17.69 $562,400 - $654,530	37,000 Added 6.06%	647,079 $10,000
Q2 2019 Aug 01, 2019	BUY	$14.75 - $17.26 $287,625 - $336,570	19,500 Added 3.3%	610,079 $10.4 Million
Q1 2019 May 02, 2019	BUY	$13.94 - $17.58 $4.37 Million - $5.51 Million	313,579 Added 113.21%	590,579 $9.51 Million
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $1.56 Million - $2.18 Million	117,000 Added 73.13%	277,000 $4.05 Million
Q3 2018 Nov 07, 2018	BUY	$16.68 - $18.41 $216,840 - $239,330	13,000 Added 8.84%	160,000 $2.91 Million
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $421,750 - $507,500	25,000 Added 20.49%	147,000 $2.48 Million
Q1 2018 May 09, 2018	SELL	$17.06 - $21.2 $238,839 - $296,800	-14,000 Reduced 10.29%	122,000 $2.39 Million
Q4 2017 Feb 07, 2018	SELL	$16.75 - $20.8 $385,250 - $478,400	-23,000 Reduced 14.47%	136,000 $2.76 Million
Q3 2017 Nov 03, 2017	BUY	$11.76 - $17.4 $1.87 Million - $2.77 Million	159,000	159,000 $2.76 Million

Others Institutions Holding HALO

# of Institutions

536

Shares Held

124M

Call Options Held

177K

Put Options Held

167K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.52B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account